Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab
Clinicaltrials.gov identifier:
NCT04493060
Study Contact Information:
Contact the Mayo Clinic Clinical Trials Referral Office by phone 855-776-0015 or by email.
Principal Investigator: Robert R. McWilliams, MD
Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab
About the Study
This study looks at how well the niraparib and the drug dostarlimab work together in treating patients with pancreatic cancer, who also have an inherited or tumor mutation in one of the following genes: , , , , , or .
- may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- such as dostarlimab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This study is no longer enrolling people.
This study is no longer enrolling people.
This study is no longer enrolling people.